OncoMatch/Clinical Trials/NCT06972576
Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer
Is NCT06972576 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including EphA2-targeted CAR-T Cells and EphA2-targeted CAR-DCs for non-small cell lung cancer.
Treatment: EphA2-targeted CAR-T Cells · EphA2-targeted CAR-DCs — This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of EphA2-targeted CAR-DC combined with CAR-T cell therapy in patients with non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EPHA2 expression ≥20% by immunohistochemistry (≥20%)
Tumor tissue tested positive for EphA2 expression by immunohistochemistry (≥20%)
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
patients must have received at least two prior systemic therapies, including but not limited to chemotherapy and immune checkpoint inhibitors
Must have received: immune checkpoint inhibitor
patients must have received at least two prior systemic therapies, including but not limited to chemotherapy and immune checkpoint inhibitors
Must have received: targeted therapy
patients with actionable driver mutations must have failed targeted therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥9 g/dL. No transfusions, G-CSF, thrombopoietin, or erythropoietin allowed within 14 days before blood tests.
Kidney function
Serum creatinine (Cr) ≤1.5×ULN, or if Cr >1.5×ULN, creatinine clearance (CrCl) ≥60 mL/min calculated using the Cockcroft-Gault formula.
Liver function
Total bilirubin (TBIL) <1.5× ULN; AST and ALT <2.5×ULN. For patients with Gilbert's syndrome, TBIL <2×ULN; if liver metastases are present, AST and ALT <5×ULN.
Adequate organ function, including: Adequate hematologic function: Absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥9 g/dL. No transfusions, granulocyte colony-stimulating factor (G-CSF), thrombopoietin, or erythropoietin allowed within 14 days before blood tests. Adequate hepatic function: Total bilirubin (TBIL) <1.5× ULN; AST and ALT <2.5×ULN. For patients with Gilbert's syndrome, TBIL <2×ULN; if liver metastases are present, AST and ALT <5×ULN. Adequate renal function: Serum creatinine (Cr) ≤1.5×ULN, or if Cr >1.5×ULN, creatinine clearance (CrCl) ≥60 mL/min calculated using the Cockcroft-Gault formula. Adequate coagulation function: Prothrombin time (PT) and activated partial thromboplastin time (APTT) <1.5×ULN; international normalized ratio (INR) <1.5 or within the target range if on anticoagulant therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify